Modafinil Arrow

Modafinil, the active ingredient in Modafinil Arrow, is a eugeroic (wakefulness‑promoting agent) presented as an oral tablet for oral use. It is prescribed to reduce excessive daytime sleepiness in adults with narcolepsy, shift work sleep disorder and obstructive sleep apnea, and improves alertness during waking hours.

GNH USA supplies Modafinil Arrow as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent manufacturing standards across all markets.

Modafinil is a central nervous system stimulant indicated for disorders characterized by excessive daytime sleepiness.

- Narcolepsy: reduces daytime sleepiness, improves ability to stay awake, and enhances overall functional performance in patients. - Shift work sleep disorder: mitigates sleepiness during night or rotating shifts, supporting better alertness and productivity for workers with irregular schedules. - Obstructive sleep apnea (excessive daytime sleepiness): lessens residual sleepiness in patients already receiving CPAP or other therapies, aiding daily activities.

Modafinil may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache: mild to moderate throbbing pain, often occurring in the temples or forehead. - Nausea: sensation of stomach upset that may lead to vomiting if severe. - Insomnia: difficulty initiating or maintaining sleep, resulting in reduced total sleep time. - Anxiety: feelings of nervousness, restlessness, or heightened tension during the day.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: rare but severe skin and mucous membrane reaction characterized by blistering and detachment. - Cardiovascular events: includes chest pain, irregular heartbeat, or significant rise in blood pressure. - Psychiatric disturbances: may manifest as hallucinations, manic episodes, or worsening of depression.

Precautions should be observed when prescribing Modafinil Arrow.

- Contraindication: avoid use in patients with known hypersensitivity to modafinil or its excipients. - Cardiovascular risk: assess blood pressure and heart disease history before initiating therapy. - Psychiatric history: monitor for emergence or worsening of anxiety, depression, or psychosis. - Liver impairment: dose adjustment may be required; evaluate hepatic function regularly. - Pregnancy and lactation: use only if potential benefit justifies potential risk; discuss with healthcare provider. - Store at ambient temperature: keep below 25 °C, in original container, protected from moisture and light.

Potential drug interactions with Modafinil Arrow should be reviewed.

Major Interactions (Avoid): - CYP3A4 inducers: drugs such as rifampicin or carbamazepine can markedly reduce modafinil plasma levels. - Hormonal contraceptives: modafinil may decrease efficacy of estrogen‑containing birth control, increasing risk of unintended pregnancy.

Moderate Interactions (Monitor Closely): - CYP2C19 inhibitors: fluvoxamine can increase modafinil concentrations, potentially enhancing side effects. - Antidepressants: concurrent use with SSRIs or SNRIs may increase risk of anxiety or insomnia. - Anticoagulants: modafinil may affect warfarin metabolism; monitor INR closely.